Combination Chemotherapy in Treating Young Patients With Advanced Solid Tumors
A Multi-Center Phase Ib Study of Oxaliplatin (NSC #266046) in Combination With Fluorouracil and Leucovorin in Pediatric Patients With Advanced Solid Tumors
Study Overview
Status
Conditions
- Unspecified Childhood Solid Tumor, Protocol Specific
- Recurrent Childhood Brain Stem Glioma
- Childhood Central Nervous System Germ Cell Tumor
- Childhood Central Nervous System Choriocarcinoma
- Childhood Central Nervous System Germinoma
- Childhood Central Nervous System Mixed Germ Cell Tumor
- Childhood Central Nervous System Teratoma
- Childhood Central Nervous System Yolk Sac Tumor
- Recurrent Childhood Central Nervous System Embryonal Tumor
- Childhood Central Nervous System Embryonal Tumor
Detailed Description
PRIMARY OBJECTIVES:
I. Determine the dose-limiting toxicities (DLT) and maximum tolerated dose (MTD) of oxaliplatin when given together with fluorouracil and leucovorin calcium in pediatric patients with recurrent or refractory solid tumors, including tumors of the CNS.
SECONDARY OBJECTIVES:
I. Determine the pharmacokinetic properties of oxaliplatin in this pediatric patient population.
II. Correlate alterations in accumulation of fludeoxyglucose F 18 with tumor response in those patients who can readily undergo a positron emission tomography (PET) or PET/CT scan.
III. Assess the safety profile of this regimen in these patients. IV. Evaluate any preliminary evidence of anti-tumor activity of this regimen in these patients.
OUTLINE: This is an open-label, multicenter, dose-escalation study of oxaliplatin. Patients are stratified according to solid tumor type (non-CNS vs CNS).
Patients receive oxaliplatin IV over 2 hours and leucovorin calcium IV over 2 hours on day 1 followed by fluorouracil IV continuously over 46 hours on days 1-2. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of oxaliplatin until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. At least 6 patients are treated at the MTD.
After completion of study treatment, patients are followed periodically.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
New York
-
New York, New York, United States, 10065
- Memorial Sloan Kettering Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Histologically diagnosed malignant solid tumor, including tumors of the CNS, that has progressed despite standard therapy or for which no effective standard therapy is known
- Patients with brainstem glioma or intrinsic pontine glioma do not need biopsy proof of the diagnosis if imaging studies are consistent with the diagnosis
- Measurable or nonmeasurable disease
- No pleural effusion or ascites causing respiratory compromise (≥ grade 2 dyspnea)
- ECOG performance status (PS) 0-2 for patients ≥ 16 years of age
- Karnofsky PS ≥ 40% for patients > 10 years of age
- Lansky Play Scale ≥ 40% for patients ≤ 10 years of age
- Peripheral absolute neutrophil count (ANC) ≥ 1,000/mm^3
- Platelet count ≥ 75,000/mm^3 (transfusion independent)
- Hemoglobin ≥ 8.5 g/dL (transfusion permitted)
- Serum creatinine ≤ 1.5 times upper limit of normal (ULN)
- Creatinine clearance OR radioisotope glomerular filtration rate > 60mL/min
- Total bilirubin < 1.5 mg/dL
- ALT and AST ≤ 2.5 times ULN (5 times ULN if liver involvement with primary tumor)
- Ejection fraction ≥ 50% OR shortening fraction ≥ 28%
- Life expectancy of > 8 weeks
No radiological evidence of pulmonary fibrosis, interstitial pneumonia, or extensive and symptomatic interstitial fibrosis of the lung
- Room air oxygen saturation ≥ 90% at altitudes ≥ 5,000 feet OR ≥ 93% at altitudes < 5,000 feet
- DLCO > 50% of predicted (for patients who received prior bleomycin and are able to comply with pulmonary function testing)
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- No history of allergic reactions attributed to compounds of similar chemical or biologic composition to platinum or oxaliplatin as well as other agents used in study treatment
- No other serious or poorly controlled social circumstance, psychiatric illness, or medical condition including, but not limited to, the following: ongoing or active infection, uncontrolled seizure disorder, uncontrolled symptomatic congestive heart failure, or cardiac arrhythmia that could be exacerbated by or complicate compliance with study therapy
- No HIV-positive patients
Recovered from prior therapy
No persistent toxicities from previous therapies ≥ grade 2
- Stable grade 3 neurotoxicity is allowed in patients with CNS tumors only who have a baseline neurotoxicity due to primary tumor involvement or postoperative complications
- At least 3 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin C)
- At least 4 weeks since prior local radiotherapy (small port)
- At least 6 months since prior craniospinal irradiation, irradiation to ≥ 50% of the pelvis, or other substantial bone marrow irradiation, including total body irradiation
- No previous treatment with oxaliplatin
- At least 14 days since prior biological therapy (including monoclonalantibody therapy)
- At least 7 days since prior retinoids, sargramostim (GM-CSF), or filgrastim (G-CSF)
- At least 14 days since prior pegfilgrastim
- No concurrent pegfilgrastim or GM-CSF
- Patients requiring steroids should be on stable or decreasing dose for ≥ 7 days prior to study entry, and must not be on more than 4 mg of dexamethasone (or equivalent) per day
At least 4 weeks since prior major surgical procedure
- Simple surgical procedures, including biopsy or central line placement or similar procedure, are allowed within 4 weeks of study entry if the patient has recovered to baseline
At least 3 months since prior autologous or allogeneic stem cell transplantation
- No concurrent immunosuppressive therapy
- No evidence of ongoing graft versus host disease (GVHD)
- No concurrent use of other investigational agents
- No other concurrent anticancer therapies or agents
- No other concurrent chemotherapy, radiation therapy, or herbal medications or supplements
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
EXPERIMENTAL: Treatment (oxaliplatin, leucovorin calcium, fluorouracil)
Patients receive oxaliplatin IV over 2 hours and leucovorin calcium IV over 2 hours on day 1 followed by fluorouracil IV continuously over 46 hours on days 1-2.
Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
|
Given IV
Other Names:
Given IV
Other Names:
Given IV
Other Names:
Correlative studies
Other Names:
Undergo PET scan
Other Names:
Undergo PET/CT scan
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
MTD based on the incidence of DLT as assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version (v.) 3.0
Time Frame: 14 days
|
14 days
|
|
DLT defined as any grade 3 or greater non-hematologic toxicity attributed to the combination of drugs in this regimen, despite maximal supportive care as assessed by NCI CTCAE v. 3
Time Frame: 14 days
|
14 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Safety profile as assessed by NCI CTCAE v. 3.0
Time Frame: 14 days
|
Any incidence of adverse events will be recorded and classified according to body region and severity.
|
14 days
|
|
Tumor response based on PET or PET/CT scan
Time Frame: From baseline to 6 weeks
|
Wilcoxon rank sum statistic will be used to assess whether tumor response is associated with the change in the PET SUV value.
|
From baseline to 6 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Lia Gore, Memorial Sloan Kettering Cancer Center
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Neoplasms by Histologic Type
- Adenocarcinoma
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Disease Attributes
- Pregnancy Complications
- Pregnancy Complications, Neoplastic
- Trophoblastic Neoplasms
- Mesonephroma
- Neoplasms
- Neoplasms, Germ Cell and Embryonal
- Recurrence
- Teratoma
- Choriocarcinoma
- Endodermal Sinus Tumor
- Germinoma
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Protective Agents
- Micronutrients
- Vitamins
- Calcium-Regulating Hormones and Agents
- Antidotes
- Vitamin B Complex
- Fluorouracil
- Oxaliplatin
- Leucovorin
- Calcium
- Levoleucovorin
Other Study ID Numbers
- NCI-2009-01051
- 04-0336
- MSKCC-040336
- CDR0000454709
- NCI-6952
- POETIC-COMIRB-040336
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.